An Enhancer Element Harboring Variants Associated with Systemic Lupus Erythematosus Engages the Promoter to Influence A20 Expression

English version České info

Functional characterization of causal variants present on risk haplotypes identified through genome-wide association studies (GWAS) is a primary objective of human genetics. In this report, we evaluate the function of a pair of tandem polymorphic dinucleotides, 42 kb downstream of the promoter of TNFAIP3, (rs148314165, rs200820567, collectively referred to as TT>A) recently nominated as causal variants responsible for genetic association of systemic lupus erythematosus (SLE) with tumor necrosis factor alpha inducible protein 3 (TNFAIP3). TNFAIP3 encodes the ubiquitin-editing enzyme, A20, a key negative regulator of NF-κB signaling. A20 expression is reduced in subjects carrying the TT>A risk alleles; however, the underlying functional mechanism by which this occurs is unclear. We used a combination of electrophoretic mobility shift assays (EMSA), mass spectrometry (MS), reporter assays, chromatin immunoprecipitation-PCR (ChIP-PCR) and chromosome conformation capture (3C) EBV transformed lymphoblastoid cell lines (LCL) from individuals carrying risk and non-risk TNFAIP3 haplotypes to characterize the effect of TT>A on A20 expression. Our results demonstrate that the TT>A variants reside in an enhancer element that binds NF-κB and SATB1 enabling physical interaction of the enhancer with the TNFAIP3 promoter through long-range DNA looping. Impaired binding of NF-κB to the TT>A risk alleles or knockdown of SATB1 expression by shRNA, inhibits the looping interaction resulting in reduced A20 expression. Together, these data reveal a novel mechanism of TNFAIP3 transcriptional regulation and establish the functional basis by which the TT>A risk variants attenuate A20 expression through inefficient delivery of NF-κB to the TNFAIP3 promoter. These results provide critical functional evidence supporting a direct causal role for TT>A in the genetic predisposition to SLE.

Vyšlo v časopise: An Enhancer Element Harboring Variants Associated with Systemic Lupus Erythematosus Engages the Promoter to Influence A20 Expression. PLoS Genet 9(9): e32767. doi:10.1371/journal.pgen.1003750
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1003750

Souhrn

Zdroje

1. JaattelaM, MouritzenH, EllingF, BastholmL (1996) A20 zinc finger protein inhibits TNF and IL-1 signaling. J Immunol 156: 1166–1173.

2. LeeEG, BooneDL, ChaiS, LibbySL, ChienM, et al. (2000) Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 289: 2350–2354.

3. BooneDL, TurerEE, LeeEG, AhmadRC, WheelerMT, et al. (2004) The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol 5: 1052–1060.

4. HitotsumatsuO, AhmadRC, TavaresR, WangM, PhilpottD, et al. (2008) The ubiquitin-editing enzyme A20 restricts nucleotide-binding oligomerization domain containing 2-triggered signals. Immunity 28: 381–390.

5. TavaresRM, TurerEE, LiuCL, AdvinculaR, ScapiniP, et al. (2010) The ubiquitin modifying enzyme A20 restricts B cell survival and prevents autoimmunity. Immunity 33: 181–191.

6. ChuY, VahlJC, KumarD, HegerK, BertossiA, et al. (2011) B cells lacking the tumor suppressor TNFAIP3/A20 display impaired differentiation and hyperactivation and cause inflammation and autoimmunity in aged mice. Blood 117: 2227–2236.

7. HovelmeyerN, ReissigS, XuanNT, Adams-QuackP, LukasD, et al. (2011) A20 deficiency in B cells enhances B-cell proliferation and results in the development of autoantibodies. Eur J Immunol 41: 595–601.

8. HammerGE, TurerEE, TaylorKE, FangCJ, AdvinculaR, et al. (2011) Expression of A20 by dendritic cells preserves immune homeostasis and prevents colitis and spondyloarthritis. Nat Immunol 12: 1184–1193.

9. YangW, TangH, ZhangY, TangX, ZhangJ, et al. (2013) Meta-analysis followed by replication identifies loci in or near CDKN1B, TET3, CD80, DRAM1, and ARID5B as associated with systemic lupus erythematosus in Asians. Am J Hum Genet 92: 41–51.

10. JostinsL, RipkeS, WeersmaRK, DuerrRH, McGovernDP, et al. (2012) Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491: 119–124.

11. Genetic Analysis of PsoriasisC, the Wellcome Trust Case ControlC, StrangeA, CaponF, SpencerCC, et al. (2010) A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet 42: 985–990.

12. KochiY, OkadaY, SuzukiA, IkariK, TeraoC, et al. (2010) A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility. Nat Genet 42: 515–519.

13. StahlEA, RaychaudhuriS, RemmersEF, XieG, EyreS, et al. (2010) Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet 42: 508–514.

14. DuboisPC, TrynkaG, FrankeL, HuntKA, RomanosJ, et al. (2010) Multiple common variants for celiac disease influencing immune gene expression. Nat Genet 42: 295–302.

15. HanJW, ZhengHF, CuiY, SunLD, YeDQ, et al. (2009) Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet 41: 1234–1237.

16. NairRP, DuffinKC, HelmsC, DingJ, StuartPE, et al. (2009) Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 41: 199–204.

17. GrahamRR, CotsapasC, DaviesL, HackettR, LessardCJ, et al. (2008) Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nat Genet 40: 1059–1061.

18. PlengeRM, CotsapasC, DaviesL, PriceAL, de BakkerPI, et al. (2007) Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat Genet 39: 1477–1482.

19. CompagnoM, LimWK, GrunnA, NandulaSV, BrahmacharyM, et al. (2009) Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 459: 717–721.

20. KatoM, SanadaM, KatoI, SatoY, TakitaJ, et al. (2009) Frequent inactivation of A20 in B-cell lymphomas. Nature 459: 712–716.

21. HonmaK, TsuzukiS, NakagawaM, TagawaH, NakamuraS, et al. (2009) TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood 114: 2467–2475.

22. ChanudetE, HuangY, IchimuraK, DongG, HamoudiRA, et al. (2010) A20 is targeted by promoter methylation, deletion and inactivating mutation in MALT lymphoma. Leukemia 24: 483–487.

23. SchmitzR, HansmannML, BohleV, Martin-SuberoJI, HartmannS, et al. (2009) TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med 206: 981–989.

24. VaughnSE, KottyanLC, MunroeME, HarleyJB (2012) Genetic susceptibility to lupus: the biological basis of genetic risk found in B cell signaling pathways. J Leukoc Biol 92: 577–591.

25. GuerraSG, VyseTJ, Cunninghame GrahamDS (2012) The genetics of lupus: a functional perspective. Arthritis Res Ther 14: 211.

26. MusoneSL, TaylorKE, LuTT, NitithamJ, FerreiraRC, et al. (2008) Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat Genet 40: 1062–1064.

27. AdriantoI, WenF, TempletonA, WileyG, KingJB, et al. (2011) Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus. Nat Genet 43: 253–258.

28. DieudeP, GuedjM, WipffJ, RuizB, RiemekastenG, et al. (2010) Association of the TNFAIP3 rs5029939 variant with systemic sclerosis in the European Caucasian population. Ann Rheum Dis 69: 1958–1964.

29. KoumakisE, GiraudM, DieudeP, CohignacV, CuomoG, et al. (2012) Brief report: candidate gene study in systemic sclerosis identifies a rare and functional variant of the TNFAIP3 locus as a risk factor for polyautoimmunity. Arthritis Rheum 64: 2746–2752.

30. ShimaneK, KochiY, HoritaT, IkariK, AmanoH, et al. (2010) The association of a nonsynonymous single-nucleotide polymorphism in TNFAIP3 with systemic lupus erythematosus and rheumatoid arthritis in the Japanese population. Arthritis Rheum 62: 574–579.

31. MusoneSL, TaylorKE, NitithamJ, ChuC, PoonA, et al. (2011) Sequencing of TNFAIP3 and association of variants with multiple autoimmune diseases. Genes Immun 12: 176–182.

32. SiggersT, ChangAB, TeixeiraA, WongD, WilliamsKJ, et al. (2012) Principles of dimer-specific gene regulation revealed by a comprehensive characterization of NF-kappaB family DNA binding. Nat Immunol 13: 95–102.

33. Kohwi-ShigematsuT, KohwiY, TakahashiK, RichardsHW, AyersSD, et al. (2012) SATB1-mediated functional packaging of chromatin into loops. Methods 58: 243–254.

34. CaiS, LeeCC, Kohwi-ShigematsuT (2006) SATB1 packages densely looped, transcriptionally active chromatin for coordinated expression of cytokine genes. Nat Genet 38: 1278–1288.

35. AinbinderE, Amir-ZilbersteinL, YamaguchiY, HandaH, DiksteinR (2004) Elongation inhibition by DRB sensitivity-inducing factor is regulated by the A20 promoter via a novel negative element and NF-kappaB. Mol Cell Biol 24: 2444–2454.

36. HindorffLA, SethupathyP, JunkinsHA, RamosEM, MehtaJP, et al. (2009) Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A 106: 9362–9367.

37. NairRP, DuffinKC, HelmsC, DingJ, StuartPE, et al. (2009) Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 41: 199–204.

38. ThomsonW, BartonA, KeX, EyreS, HinksA, et al. (2007) Rheumatoid arthritis association at 6q23. Nat Genet 39: 1431–1433.

39. TrynkaG, ZhernakovaA, RomanosJ, FrankeL, HuntKA, et al. (2009) Coeliac disease-associated risk variants in TNFAIP3 and REL implicate altered NF-kappaB signalling. Gut 58: 1078–1083.

40. HagegeH, KlousP, BraemC, SplinterE, DekkerJ, et al. (2007) Quantitative analysis of chromosome conformation capture assays (3C-qPCR). Nat Protoc 2: 1722–1733.

41. DekkerJ (2006) The three ‘C’ s of chromosome conformation capture: controls, controls, controls. Nat Methods 3: 17–21.